From receptor mismatch to risky human-animal interfaces, this article explains why spillover is common but true pandemic emergence remains rare.
Introduction
Humans are constantly exposed to animal viruses through farming, wildlife contact, and the environment; however, most animal viruses never reach pandemic potential. Successful spillover events are uncommon, as viruses must navigate complex biological, ecological, and evolutionary barriers before human-to-human transmission can occur. In the spillover cascade, an infected reservoir host must shed enough virus, the virus must survive or be carried to a susceptible human, and infection must then progress to onward transmission; failure at any one step can stop emergence.1,5 These barriers are also shaped by human behavior, land-use change, wildlife trade, farming systems, and other interfaces that determine how often people encounter infectious animals or contaminated environments.1,2,3,5
Biological barriers to zoonotic adaptation
Receptor incompatibility limits efficient animal-to-human transmission, as animal viruses rarely bind to human receptors with optimal efficiency, thereby restricting their entry into host cells. For example, avian influenza viruses preferentially bind to SAα-2,3 receptors in birds, whereas human influenza strains preferentially bind to SAα-2,6 receptors in the human upper respiratory tract.2 Because SAα-2,3 receptors are found mainly deeper in the human respiratory tract, some avian influenza viruses may infect exposed people yet still transmit poorly between humans.2
Many animal viruses that can enter human cells still fail to complete the human-cell replication cycle, including genome replication, assembly, budding, fusion, and release, because they cannot always use the required human host factors efficiently.4,5 Thus, despite entering the host, most viruses cause dead-end spillover infections, rather than sustained transmission. Collectively, failure to bind host cell receptors, evade immunity defenses, or replicate efficiently within human cells results in a self-limiting event. 4,5
Transmission dynamics and ecological constraints
The route of pathogen shedding strongly influences transmission potential. For many efficiently transmitted respiratory viruses, replication and shedding in the upper respiratory tract can facilitate spread, but transmission also depends on infectious dose, tissue tropism, host behavior, and environmental survival.2,3,5
Infection by many animal viruses requires high-dose exposure, vector bites, contaminated food, or close contact with bodily fluids, which sharply limits opportunities for onward human transmission.1,5 For example, avian influenza viruses can infect humans exposed to infected poultry; however, these pathogens do not efficiently transmit between humans due to poor replication in the upper respiratory tract.2
To maintain continuous transmission, a virus must encounter new, uninfected individuals faster than infected individuals recover or die. In epidemiological terms, sustained spread usually requires the basic reproductive number, R0, to remain above 1.5 If human population density is low or spillover events occur in isolated rural areas, the virus naturally exhausts its pool of susceptible hosts for transmission.

Biological data needed to understand and predict spillover (left) aligned to the key mechanisms of spillover (right). In addition, epidemiology and social sciences are employed to understand human exposure. Adapted from Plowright et al.
Conversely, dense farms, live-animal markets, shelters, transport networks, and highly connected urban centers can increase contact rates and create more opportunities for rare spillovers to be amplified.2,3,5
Short infectious periods and the ecological dependence on specific wildlife hosts or seasonal vectors similarly disrupt transmission dynamics. Moreover, environmental survival outside the host is itself a barrier to spillover, because heat, desiccation, ultraviolet (UV) light, and other conditions can reduce the infectious dose that reaches people.1
Evolutionary bottlenecks and viral adaptation limits
Animal viruses constantly evolve through mutations, recombination events, and genetic reassortment; however, only a small fraction acquire the combination of genetic traits required to adapt to human systems for sustained transmission. Importantly, genetic mutations may come at an evolutionary cost, as alterations in viral surface proteins that improve binding to host cell receptors can become unstable in the original host, limiting the virus’s ability to survive and spread.2,4
Ribonucleic acid (RNA) viruses, such as coronaviruses and influenza viruses, evolve rapidly because their replication processes generate frequent genetic changes. Recombination events in the coronavirus spike protein receptor-binding domain can alter host range and receptor recognition.2,4 For segmented viruses such as influenza A, reassortment can also create novel gene combinations, but most such combinations are not fit enough to spread efficiently in humans.2
Viruses may utilize intermediate hosts to gradually adapt to new species. The human immunodeficiency virus (HIV), for example, arose after simian immunodeficiency viruses crossed from non-human primates, including chimpanzees and gorillas, into humans; these primates are better described as source or bridging hosts than as simple “intermediate evolutionary hosts.”5
Intermediate hosts may possess cellular receptors compatible with both the original animal reservoir and humans, thereby facilitating viral replication while gradually accumulating adaptive mutations. They may also amplify exposure by bringing the virus closer to people, as observed in coronavirus spillover events involving civets, camelids, farmed animals, and other domestic and captive mammals.3 However, intermediate hosts are not required for every emergence event, and their importance depends on the virus, reservoir ecology, and level of human exposure.1,3,5
Importantly, successful transitions remain rare, as most viruses fail to bypass the complex evolutionary constraints required for stable viral host adaptation and pandemic emergence.5
Image Credit: Lightspring / Shutterstock.com
Emerging research, surveillance, and future directions
Recent advances in genomic surveillance have enabled proactive research to identify viruses with the potential to threaten human health. Collaborative efforts such as the United States Agency for International Development (USAID) PREDICT initiative and the proposed Global Virome Project have expanded viral discovery and highlighted the need to connect sequence data with ecological and functional evidence.3,5
By using metagenomic sequencing of wildlife and high-risk human-animal interfaces, scientists can prioritize viruses and settings for further investigation, but they cannot yet predict pandemic emergence with certainty from sequence data alone.4,5
Furthermore, artificial intelligence (AI) and machine learning (ML) models are improving zoonosis risk assessment by integrating viral genomics, ecological disruption, wildlife movement, and human exposure patterns. These models analyze complex variables like host density, habitat loss, and receptor configuration of uncharacterized viruses to prioritize high-risk host-virus interfaces and guide targeted functional testing, rather than definitively identifying future pandemic viruses.4,5 Such tools are best viewed as hypothesis-generating systems that must be paired with field ecology, experimental infection studies, and public-health surveillance.4,5
Next-generation vaccines are further strengthening pandemic preparedness, as demonstrated by the rapid development and deployment of messenger RNA (mRNA) vaccines during the coronavirus disease 2019 (COVID-19) pandemic. However, the reviewed spillover literature emphasizes that medical countermeasures usually act after exposure or emergence, whereas the most complete form of pandemic prevention is to prevent the spillover event itself.5
To overcome the time-consuming timelines of single-virus vaccines, researchers are investigating pan-viral approaches that target highly conserved regions of viral families to confer protection against multiple viruses.
Functional viromics, in silico receptor modeling, in vitro entry and replication assays, and in vivo transmission studies can help connect viral genotypes to phenotypes and prioritize multivalent vaccines or therapeutics before an outbreak escalates.4,5
A One Health approach also emphasizes upstream prevention, including reducing risky wildlife contact, improving domestic-animal management, monitoring high-risk interfaces, and addressing environmental changes that increase spillover pressure.1,3,5
References
- Plowright, R., Parrish, C., McCallum, H. et al. (2017). Pathways to zoonotic spillover. Nature Reviews Microbiology 15; 502-510 (2017). DOI: 10.1038/nrmicro.2017.45, https://www.nature.com/articles/nrmicro.2017.45
- Alvarez-Munoz, S., Upegui-Porras, N., Gomez, A. P., & Ramirez-Nieto, G. (2021). Key Factors That Enable the Pandemic Potential of RNA Viruses and Inter-Species Transmission: A Systematic Review. Viruses 13(4); 537. DOI: 10.3390/v13040537. https://www.mdpi.com/1999-4915/13/4/537
- Nova, N. (2021) Cross-Species Transmission of Coronaviruses in Humans and Domestic Mammals, What Are the Ecological Mechanisms Driving Transmission, Spillover, and Disease Emergence? Frontiers in Public Health 9. DOI: 10.3389/fpubh.2021.717941. https://www.frontiersin.org/journals/public-health/articles/10.3389/fpubh.2021.717941/full
- Letko, M., Seifert, S.N., Olival, K.J. et al. (2020). Bat-borne virus diversity, spillover and emergence. Nature Reviews Microbiology 18; 461-471. DOI: 10.1038/s41579-020-0394-z. https://www.nature.com/articles/s41579-020-0394-z
- Plowright, R. K., & Hudson, P. J. (2021). From Protein to Pandemic: The Transdisciplinary Approach Needed to Prevent Spillover and the Next Pandemic. Viruses 13(7); 1298. DOI: 10.3390/v13071298. https://www.mdpi.com/1999-4915/13/7/1298
News – Curated by Amanda Scott, Alias Group Creative
Follow her on Bluesky
FDA Clears First-of-Its-Kind Nonmedication Treatment for PTSD
The FDA has cleared a system that uses brain activity data to personalize magnetic stimulation for PTSD, adding a new nonmedication treatment option. Every day in the United States, approximately 17.5 veterans die by suicide, [...]
FDA approves breakthrough drug to treat advanced pancreatic cancer
The Food and Drug Administration (FDA) approved on Wednesday a drug that could extend the survival of those with metastatic pancreatic cancer. The drug, called daraxonrasib, will be sold under the brand name Rasonque [...]
AI Decodes a Hidden DNA Signal Linked to Disease-Causing Mutations
Machine learning identifies the likely “initiator” and enables new predictions about DNA mutations that can cause disease. Every human cell depends on tens of thousands of genes being switched on at the right time [...]
Pope Leo Urges Global Response to Congo’s Deadliest Ebola Outbreak
Pope Leo called for international action to address the Ebola outbreak in the Democratic Republic of Congo. The epidemic has claimed over 2,500 lives and is the nation's largest recorded outbreak. The Pope emphasized [...]
Is there a summer COVID-19 surge this year? Yep, it’s ramping up again
Hantavirus. Ebola. West Nile. Measles. And, of course, cyclospora — that stomach parasite making people miserable across the country. Americans have plenty to worry about this summer. But remember COVID-19? It may not be [...]
Natural Compound in Broccoli Could Help Treat a Rare, Incurable Neurological Disease
Swinburne researchers have discovered how broccoli could help treat an extremely rare and incurable disease that affects only about 200 Australians. A naturally occurring compound in broccoli is being investigated as a possible treatment [...]
Antibody recycling, FcRn and the next generation of biologics
FcRn plays a central role in regulating the half-life of IgG antibodies and albumin, making it a critical target in both antibody engineering and autoimmune disease therapy. This article explores the biology of FcRn, [...]
Ebola kills 2,300 in three months with no vaccine available for Congo’s deadliest ever outbreak
It’s Congo’s 17th outbreak, with a toll that has eclipsed that of the country’s 2018-2020 outbreak when 2,299 deaths out of 3,481 cases were recorded. The latest data shows 101 new cases and 33 [...]
Beyond an Agency: How AI, Creativity and Commercialization Are Converging Into a New Growth Model
At a moment when AI is forcing a fundamental rethink of how work gets done, the life sciences industry is grappling with a deeper question: what role should human creativity play in an increasingly [...]
New $60 Blood Test Detects Lung Cancer Without Costly DNA Sequencing
A simple blood test that detects chemical changes in DNA identified more than 90% of stage 2-4 lung cancers in an early study, without relying on costly DNA sequencing. Researchers at Tel Aviv University and collaborating [...]
Reducing drug development failures with human-relevant models and AI
Professor Joseph C. Wu of Stanford University explains how stem cells, human-relevant models and AI are helping researchers predict which drug candidates are most likely to succeed before clinical trials. Researchers now have access [...]
Half of vaccines are binned – ‘fridge-free’ versions could change that
Vaccines that do not need to be kept cool in a fridge have been successfully trialed in patients for the first time, say UK scientists. Currently, most vaccines need to be refrigerated or frozen [...]
Mushroom Mystery: The Fungus That Makes People See Tiny Humans
A mushroom sold in markets and served in restaurants in Southwest China has an unusual warning attached to it: cook it thoroughly, or you may start seeing tiny people. For decades, people have reported [...]
Artificial intelligence used to design brand new viruses
Artificial Intelligence has been used to design brand new viruses that are fully functional and can replicate in the laboratory, say US researchers. It is the first time whole genomes have been successfully designed [...]
Molecular Manufacturing: The Future of Nanomedicine – New book from NanoappsMedical Inc.
This book explores the revolutionary potential of atomically precise manufacturing technologies to transform global healthcare, as well as practically every other sector across society. This forward-thinking volume examines how envisaged Factory@Home systems might enable the cost-effective [...]
Moderna kicks off Phase I Ebola trial as Africa readies itself for research
If the Phase I trial is successful, Moderna plans to quickly initiate Phase II and Phase III trials of its Ebola vaccine. Moderna has initiated a Phase I trial of its mRNA Ebola vaccine [...]















